Since the advent of the Kidney Allocation System (KAS), matched candidates with high (>98%) panel reactive antibody (hPRA) are given priority over local candidates with lower PRA. This often leads to exporting of kidneys. Data for these kidneys are not detailed on routine reports. Twenty-two organ procurement organizations prospectively submitted data from August 2015 to July 2016, describing allocation practices of kidneys to hPRA patients and outcomes of these kidneys. Five hundred twenty out of 6924 procured kidneys were exported for hPRA recipients. Of these, 402 (77.3%) were transplanted into the intended recipient (IR); 100 (19.2%) were transplanted into unintended recipients (UR), and 18 (3.5%) were discarded. The most common reason for use in an UR was a positive crossmatch (XM) (63%). The most common reasons for discard were donor quality (44%) and ischemic time (39%). Prior to kidney export, when tissue crossmatching was done, 96.2% of the kidneys went to the IR, versus 80.7% following virtual CM, versus 56.7% when no crossmatching was performed (p < 0.0001). A significant number of kidneys exported for hPRA patients are not being used in the IR or are being discarded. The most common reason for this is positive tissue XM. We report that unintended use of the kidney was minimized when tissue was shipped and XM results were known prior to exporting the kidney.
Introduction
The new Kidney Allocation System (KAS) by the Organ Procurement and Transplantation Network (Organ Procurement and Transplantation Network) became active on December 4, 2014. One of the implementations of this system was the increased regional/national sharing of kidneys for patients who have calculated Panel Reactive Antibody (cPRA) levels above 98% (hPRA). From an Organ Procurement Organization (OPO) perspective, this practice change led to uncertainty about how to optimize kidney utilization in light of potential new challenges with transportation, interaction with multiple different transplant programs, and varied practices in histocompatibility verification.
Patients with hPRA represent about 8% of the waiting list. In the 1 year since implementation, the proportion of transplants occurring in these specific patients rose significantly from 2.4% to 13.4% (1) , but this has now plateaued at about 10% (2) after 18 months of KAS being in effect. Overall kidney discard rates initially rose to 20.2% during the first 6 months (2-5), but have now returned to pre-KAS levels. There is sparse data detailing the use of kidneys specifically exported for hPRA patients. There are concerns that some of these kidneys may be transplanted into an unintended recipient (UR) or discarded. United Network for Organ Sharing (UNOS) reports detail that initially almost 30% of kidneys allocated to the hPRA group were transplanted into UR, a number that dropped to 17.7% after a full year of KAS. Details such as cause for UR transplant or discard, specifics of crossmatching, and OPO strategies to prevent unintended use are not available. Accordingly, the objective of our study was to provide specific details of kidneys shipped outside a Donation Service Are (DSA) for hPRA patients, looking specifically at OPO practices and the outcomes of these kidneys.
Reducing unintended use of these kidneys could help prevent unintended allocation and discard of these kidneys.
Methods
A prospective study was conducted from August 2015 to July 2016, looking at OPO operational practices regarding allocation of kidneys to hPRA patients. The study excluded kidneys allocated to multivisceral recipients. We evaluated OPO practices for hPRA kidney exports, including mandating crossmatches (XMs) prior to export of kidneys, arranging for recipient backup (either at the exporting or recipient DSA), HLA typing, and eventual outcomes of these exported kidneys. The study was conceived by the Organ Donation Research Consortium, and was supported by a grant from the LifeLink Legacy Fund to assist in the collection and interpretation of data. Ultimately, 22 OPOs volunteered to participate in this study.
Data were analyzed by an unpaired two-tailed t-test for continuous variables. Categorical variables were analyzed using a Fisher's exact test or chi-square test, depending on the number of variables (GraphPad, La Jolla, CA). For comparison of multiple groups, a one-way analysis of variance was performed with a post hoc Tukey multiple comparison test for statistically significant variables. A p value ≤0.05 was considered to be significant. All data are presented as mean AE standard error of the mean unless otherwise noted.
Results

Demographics
Out of a total of 6924 procured kidneys from the 22 OPOs, 520 (7.5%) were exported out of the DSA for hPRA recipients. Of these 520 kidneys, 402 (77.3%) were transplanted into the intended recipient (IR), 100 (19.2%) were transplanted into URs, and 18 (3.5%) were discarded.
Kidney biopsies were performed in 171 (32.9%) of the exported kidneys. The mean percentage of glomerular sclerosis (GS) was 4%, and the median percentage of GS was 1% (range 0-59%). One hundred one kidneys (19.4%) were preserved with cold pulsatile pump perfusion by the OPO prior to export. In 46 (45.5%) of these 101 pumped kidneys, results of tissue XM were known prior to shipping.
Unintended recipient (UR) and kidney discard
Of the 100 kidneys that were transplanted into URs, 43 were at the IR DSA, 40 were shipped back to the original DSA, and 17 were sent to a third DSA for transplant. The most common reasons for use in a UR included positive XM (64%), poor kidney quality (20%), recipient issues (11%), and transportation issues (4%) ( Table 1) .
For the 18 kidneys that were discarded, the reasons included donor quality/anatomy (44%), long cold ischemic time (39%), surgical damage (11%), and improper packaging (6%) ( Table 1 ). The mean Kidney Donor Profile Index (KDPI) score for all kidneys was 38%; the average KDPI for the kidneys transplanted was 37%, and that for the discards was 52%. Ten discarded kidneys had biopsies. The discarded kidneys had significantly higher GS than those utilized (mean 28.0 AE 7.9% vs. 4.4 AE 0.7%, p < 0.0001). Additionally, of the discarded kidneys that were biopsied, 60% (n = 6/10) had more than 20% of the glomeruli sclerosed (vs. 4.3%, n = 7/161 in the utilized group, p ≤ 0.0001).
HLA typing and XM details
Whole blood for XM was sent prior to recovery in 292/ 520 (56.2%) of these cases, of which negative XM results were confirmed in 214 (73.3%) prior to kidney export. Two hundred six of these kidneys were transplanted into the IR (96.2%), with 3 discards. One hundred fourteen of 520 recipients had pre-export virtual XM results only, of which 16 (14%) had subsequent positive tissue XM found after export. In 192/520 instances, there was no histocompatibility testing done prior to kidney export and of these, 47 (24%) had subsequent positive tissue XMs. Overall, 96.2% of kidneys with pre-export tissue XM went into IRs, compared to 80.7% for those who had virtual XM only, and 54.2% who had no XM done prior to shipping (p < 0.0001). Details of these are depicted in Figure 1 . DP/DQA typing was performed for 87% of kidneys (452/ 520). When DP/DQA typing was performed, 19% (86/ 452 kidneys) were transplanted into an UR. In the 68 cases where typing was not done, 14 (21%) kidneys were transplanted into an UR (p = 0.7429). UNOS policy allowed transplant centers to list DP/DQA unacceptable antigens after January 21, 2016. We broke down the rate of positive XMs before and after this date. Before the policy change, 69 kidneys went into UR, of which 43 were due to positive XM. After the policy change, 31 kidneys went into UR, of which 21 were due to positive CM (43/69 vs. 21/31; p = 0.6577). were transplanted into the local backup patient, 10 (20.4%) were discarded, and 4 (8.2%) were transplanted at a third DSA. In contrast, local back-up was not granted in 316/520 (60.8%) cases. Of the 316 cases, 69 (21.8%) were not transplanted into intended recipient (p = 0.59 when compared to kidneys with local backup that were not transplanted into the IR). With regard to these 69 kidneys, 40 (58%) were returned to the donor OPO and transplanted, 8 (11.6%) were returned to the donor OPO and discarded, 13 (18.8%) were sent to a third DSA, and 8 (11.6%) remained in the DSA of the IR, yet were transplanted into another patient.
Kidney ischemic times and distance traveled
The mean cold ischemic time for kidneys transplanted into IRs was 21.1 AE 0.5 h; for kidneys that went into URs, it was 22.7 AE 1.0 h (p = 0.1349). On further breakdown, it appeared that the cold ischemic time for UR transplanted into a local backup at the IR DSA was less compared to shipping it back to the original DSA (17.9 AE 1.5 h vs. 25.6 AE 1.3 h, p < 0.0001) or shipping it to a third DSA (17.9 AE 1.5 h vs. 25.8 AE 1.4 h, p < 0.0001). The average distance traveled for kidneys that went into IRs was 796 AE 51 miles versus 899 AE 81 miles for those used in UR (p = 0.2731).
Discussion
We are just starting to understand the consequences of the new KAS, including the concern regarding unintended use of procured organs. This study is unique in that it details specifics of kidneys specifically exported for hPRA patients that are not available with routine reports.
While the overall discard rate of kidneys nationally may remain at about 18% (2-4), it is important to interpret this with caution in the current study. Transplant centers that accept imported kidneys have access to donor information such as anatomy and biopsy results, in addition to routine donor information that is available prerecovery. A damaged kidney or one with poor quality identified at recovery would less likely be accepted for import, suggesting that higher quality kidneys are being exported. In this study, the average KDPI for the discarded kidneys was 52%. Eight kidneys were discarded for long ischemic times or packaging issues, suggesting that these were related to their export status.
In this study, we identified that kidneys were more likely to be transplanted into the intended recipient when tissue XMs were done prior to export of the kidney.
From an OPO perspective, we recognize that prior reports have already demonstrated an increase in workload for hPRA kidneys, including an increase in tissue shipping for XM (6) . This is accompanied by increase in cost and transportation and potential delay of procurement and is admittedly challenging to implement nationally. However, we identified that sending tissue ahead of recovery was beneficial; 96.2% of kidneys were used in the IR when XM was done, versus 54.2% when no compatibility was performed prior to export.
The use of machine perfusion of kidneys is variable across the country. In a study by Cannon et al (7), a retrospective UNOS review of kidneys transplanted between 2005 and 2011 showed that 9882/36 323 (27%) of kidneys procured, not all from extended donors, were machine pumped prior to transplant. It is possible some OPOs may do this to await XM results. We saw that 46% of pumped kidneys had tissue XM results available prior to export. This may be another strategy to help unintended use.
In this study, OPO practice was generally to send whole blood for tissue XM rather than donor spleen or lymphatic tissue, though we lacked specific data. It has been demonstrated that HLA Class I and II expression is significantly lower in deceased donor blood when compared to lymphatic tissue and that this may impact XM outcomes (8) . Although some OPOs reported the capability to recover lymphatic tissue prerecovery in the intensive care unit, this practice is not universally employed due to coordinator experience and donor hospital and family preference.
Using a virtual XM may alleviate some unintended use. However, in this study we showed that even after negative virtual XM, 14% of IRs had subsequent positive tissue XMs. A virtual XM is only as good as the unacceptable antigens that need to be updated and listed. Transplant centers have different unacceptable antigen listing and acceptance criteria designating a variable risk tolerance (9) . Single antigen bead HLA antibody testing identifies antibodies against broad HLA antigens, but only a small number of allele-specific HLA antibodies. A candidate may have antibody reactivity to a specific HLA allele and centers may consider the parent HLA antigen acceptable to facilitate organ offers (10) . Hence a seemingly compatible transplant may in fact be incompatible due to unidentified allele-specific antibodies.
Tambur et al (11) report that as many as 16% of sensitized individuals should expect a positive XM. Many of these XM issues may be related to transplant centers not listing antigens at the DP and/or DQA locus, or HLA labs not performing this testing. Bray et al (12) have reported that up to 63% of patients with cPRA of >98% have HLA antibodies to DPB1 and/or DQA1. In a 2014 study by Kucheryavaya et al (13) , the authors report that only approximately one third of HLA laboratories in the United States were performing HLA testing for the DP and DQ locus. On January 21, 2016, the OPTN Board of Directors required that donors and patients be prospectively typed for the DPB1 and DQA1 locus, and that OPTN develop the capability to list these antigens as unacceptable (14) . In this study, 87% of the kidneys were typed for DQA and DPB; however, we are unable to comment on how many positive XMs were the result of antibodies to DQA and/or DPB. This study included the time period affected by the change in policy, and did not identify any significant change in the rate of positive XM before versus after the policy change; however, further investigation is needed in this area.
We found that OPOs granted "local backup" in less than half (39.2%) of hPRA kidney allocations. We found that the rate of transplant into an UR was similar regardless of whether local backup was granted (24.5% vs. 21.8%, respectively, p = 0.5925). There were no statistically significant differences noted in discard rate when local backup was granted (20% versus 12% of those returned to the donor DSA, p = 0.21); however, the study is underpowered to make a meaningful conclusion and we recognize that these results may be biased in that OPOs are more likely to grant local backup when the kidney is of lower quality. It is interesting that the cold ischemic times for the kidneys that went into URs were only slightly longer than those that went into IRs. This may be due to good advance planning and possibly having backup recipients performing XM at the same time as the IR. In the report by Stewart et al (1), we recognize that kidneys transplanted into these recipients may have much longer to travel and have longer cold ischemic times, so planning for this is essential. The current study found the shortest ischemic times when the kidney went to a local backup at the IR's DSA.
Although this study describes novel findings regarding specific OPO practices that impact kidney allocation to hPRA recipients, it has several limitations. The study involved 22 OPOs and more than 100 transplant centers. Each center has unique and variable practices with regard to histocompatibility, listing of avoid antigens, and tolerance for positive XM in the face of non-HLA antibody. We are unable to comment on the specifics regarding interpretation of XM at the various centers that may have impacted allocation. We also lack information regarding XM techniques and thresholds for incompatible antigens, and recognize that this variability in practice impacts kidney utilization. We also caution interpretation of the data of tissue versus virtual XM. This may not represent a true comparison as we cannot account for situations where tissue could/would not be sent and hence a virtual XM was the candidate's only option.
Conclusions
A significant number of kidneys exported for high (>98%) PRA patients are not being used in the IR or are being discarded. The most common reason for this is positive tissue XM in the IR. Unintended use of the kidney was minimized when donor tissue was shipped and XM results were known prior to exporting the kidney. This study helps elaborate details of unintended consequences of kidneys exported for high PRA patients, and may help develop strategies to facilitate allocation into the IR.
